Forensic Exams Computer forensics, best practices, and reviews

Basic Information About KBI Biopharma

Most people have heard about the important of biopharmaceutical development to find safe and effective treatments for everything from mild illnesses to more serious diseases such as cancer, hepatitis, HIV and AIDS. KBI Biopharma is one of the leaders in this biopharmaceutical industry.

The company, based near the Research Triangle Park area of Durham, North Carolina, works with global firms to develop pharmaceutical and biotechnological health care solutions. Some of its operations involve streamlining protein characterization processes to help create injectable medical treatments. KBI was founded in 1996.

Most funding for KBI Biopharma comes from private investors such as Ballast Point Ventures in St. Petersburg, Florida. The private venture capital firm focuses primarily on businesses operating in the southeastern United States. Some of their chief executives have extensive biotechnical experience, which enables them to decide with which biopharmaceutical companies they should invest funds. In 2009, Ballast Point Ventures invested $7.4 million in KBI Biopharma.

The financial reliance on private investors rather than pharmaceutical companies or government agencies allows companies to research and execute their plans without interference from parties which may have their own medical or political agenda to promote. Traditional investors simply hope to make a profit, but usually do not intend to promote or deny specific types of medical treatment.

Regardless of the investment source, oral and injectable drug development is an extensive process that requires adherence to ethical as well as legal guidelines. KBI representatives and their partners take a treatment through six phases. Once a treatment has been proven safe and effective, it can go to agencies such as the United States Food and Drug Administration for approval. Europe has similar government agencies. In some cases, a safe and effective treatment may be available in another country before it can be legally used in the United States.